IMPEDIMED LIMITED — Share Issue/Capital Change 2015

Mar 5, 2015

==> picture [108 x 100] intentionally omitted <==

----- Start of picture text ----- ASX: IPD----- End of picture text -----

6 March 2015

ASX ANNOUNCEMENT

Notification of Release of Restricted Shares from Escrow

Brisbane, Australia – ImpediMed Limited (ASX: IPD) advises that in accordance with Listing Rule 3.10A 85,000 fully paid ordinary shares currently held under escrow are being released on 20 March 2015.

There are no further restricted shares on issue.

Cherrell Hirst AO Chairman

About ImpediMed

ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit: www.impedimed.com.au

Page 1 of 1